Finance

Lists
6Z4:FRA
Crinetics Pharmaceuticals Inc
€71.58
0.00%
(0.00) 1D
Aug 31, 9:06:04 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 6Z4...
Mkt. cap
9.01B
Avg. vol.
0.00
Volume
0.00
52-wk high
€73.08
52-wk low
€26.40
No. of employees
594
Mkt. cap
9.01B
Avg. vol.
0.00
Volume
0.00
52-wk high
€73.08
52-wk low
€26.40
No. of employees
594
News stories
From web sources and news partners
Profile
Crinetics Pharmaceuticals was a global pharmaceutical company known for developing drugs for the treatment of endocrine-related diseases. It was founded by Scott Struthers, Frank Zhu, Ana Kusnetzow, and Stephen F. Betz in 2008 and is headquartered in San Diego, California. It went public on NASDAQ in 2018. In July 2026, Vertex Pharmaceuticals agreed to acquire the company for $10 billion. The acquisition closed in September of 2026. Wikipedia
About Crinetics Pharmaceuticals Inc
CEO-
Employees594
FoundedNov 18, 2008
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
143.00K
6.16M
10.73M
25.12M
Cost of goods sold
90.46M
86.13M
100.28M
100.00M
Cost of revenue
90.46M
86.13M
100.28M
100.00M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
52.26M
53.70M
50.83M
57.57M
Operating expense
52.26M
53.70M
50.83M
57.57M
Total operating expenses
142.73M
139.83M
151.11M
157.58M
Operating income
-142.59M
-133.67M
-140.38M
-132.46M
Other non operating income
-49.00K
-125.00K
-131.00K
-423.00K
EBT including unusual items
-130.09M
-122.64M
-127.84M
-120.86M
EBT excluding unusual items
-130.09M
-122.64M
-127.84M
-120.86M
Income tax expense
-
180.00K
-
-
Effective tax rate
-
-0.15%
-
-
Other operating expenses
-
-
-
-
Net income
-130.09M
-122.82M
-127.84M
-120.86M
Net profit margin
-90,972.73%
-1,993.43%
-1,191.03%
-481.15%
Earnings per share
-1.38
-1.29
-1.23
-1.14
Interest and investment income
12.54M
11.16M
12.66M
12.03M
Interest expense
-
-
-
-
Net interest expenses
12.54M
11.16M
12.66M
12.03M
Depreciation and amortization charges
-
-
-
-
EBITDA
-141.57M
-132.67M
-139.22M
-131.39M
Gain or loss from assets sale
-
8.00K
20.00K
-
AI content may include mistakes. Learn more
Google apps